Latest period
$555.00M
YoY change
+9.1%
5Y CAGR
-6.6%
Peak year (2020)
$779.00M
Latest annual
$553.00M
Stock-Based Compensation history chart for Bristol-Myers Squibb (BMY) from 1989 to 2025
Latest: $553.00M
Stock-Based Compensation growth chart for Bristol-Myers Squibb (BMY) from 1989 to 2025
Latest: +9.1%
Stock-Based Compensation history table for Bristol-Myers Squibb (BMY) from 1989 to 2025
| 2025 | $553.00M | +9.1% | +$46.00M | ||
| 2024 | $507.00M | -2.1% | −$11.00M | ||
| 2023 | $518.00M | +13.3% | +$61.00M | ||
| 2022 | $457.00M | -21.6% | −$126.00M | ||
| 2021 | $583.00M | -25.2% | −$196.00M | ||
| 2020 | $779.00M | +76.6% | +$338.00M | ||
| 2019 | $441.00M | +99.5% | +$220.00M | ||
| 2018 | $221.00M | +11.1% | +$22.00M | ||
| 2017 | $199.00M | -2.9% | −$6.00M | ||
| 2016 | $205.00M | -12.8% | −$30.00M | ||
| 2015 | $235.00M | +10.3% | +$22.00M | ||
| 2014 | $213.00M | +11.5% | +$22.00M | ||
| 2013 | $191.00M | +24.0% | +$37.00M | ||
| 2012 | $154.00M | -4.3% | −$7.00M | ||
| 2011 | $161.00M | -16.6% | −$32.00M | ||
| 2010 | $193.00M | +5.5% | +$10.00M | ||
| 2009 | $183.00M | +1.1% | +$2.00M | ||
| 2008 | $181.00M | — | +$181.00M | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | $0.00 | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | $0.00 | ||
| 1999 | $0.00 | — | $0.00 | ||
| 1998 | $0.00 | — | $0.00 | ||
| 1997 | $0.00 | — | $0.00 | ||
| 1996 | $0.00 | — | $0.00 | ||
| 1995 | $0.00 | — | $0.00 | ||
| 1994 | $0.00 | — | $0.00 | ||
| 1993 | $0.00 | — | $0.00 | ||
| 1992 | $0.00 | — | $0.00 | ||
| 1991 | $0.00 | — | $0.00 | ||
| 1990 | $0.00 | — | $0.00 | ||
| 1989 | $0.00 | — | — |
- 2025$553.00M+9.1%
- 2024$507.00M-2.1%
- 2023$518.00M+13.3%
- 2022$457.00M-21.6%
- 2021$583.00M-25.2%
- 2020$779.00M+76.6%
- 2019$441.00M+99.5%
- 2018$221.00M+11.1%
- 2017$199.00M-2.9%
- 2016$205.00M-12.8%
- 2015$235.00M+10.3%
- 2014$213.00M+11.5%
- 2013$191.00M+24.0%
- 2012$154.00M-4.3%
- 2011$161.00M-16.6%
- 2010$193.00M+5.5%
- 2009$183.00M+1.1%
- 2008$181.00M—
- 2007$0.00—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
- 2001$0.00—
- 2000$0.00—
- 1999$0.00—
- 1998$0.00—
- 1997$0.00—
- 1996$0.00—
- 1995$0.00—
- 1994$0.00—
- 1993$0.00—
- 1992$0.00—
- 1991$0.00—
- 1990$0.00—
- 1989$0.00—
Stock-Based Compensation values are taken from Bristol-Myers Squibb's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Bristol-Myers Squibb (BMY)
Stock-Based Compensation for Bristol-Myers Squibb (BMY): headline value $555.00M · YoY +9.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Bristol-Myers Squibb (BMY) most recent annual stock-based compensation stands at $553.00M (2025) – grew 9.1% year-over-year.
Bristol-Myers Squibb stock-based compensation has contracted on net over the period, with a -6.6% compound annual growth rate over 2020–2025 (5 years).
Across the available history, stock-based compensation reached its high of $779.00M in 2020 and its low of $0.00 in 1989.
Bristol-Myers Squibb Stock-Based Compensation by Year
Bristol-Myers Squibb Stock-Based Compensation 2025: $553.00M
Bristol-Myers Squibb posted stock-based compensation of $553.00M in 2025, grew 9.1% from 2024.
Bristol-Myers Squibb Stock-Based Compensation 2024: $507.00M
In 2024, Bristol-Myers Squibb reported stock-based compensation of $507.00M, edged down 2.1% below 2023.
Bristol-Myers Squibb Stock-Based Compensation 2023: $518.00M
Bristol-Myers Squibb stock-based compensation in 2023 was $518.00M, grew 13.3% from 2022.
Bristol-Myers Squibb Stock-Based Compensation 2022: $457.00M
2022's stock-based compensation for Bristol-Myers Squibb came in at $457.00M, declined 21.6% below 2021.
Bristol-Myers Squibb Stock-Based Compensation 2021: $583.00M
Bristol-Myers Squibb stock-based compensation in 2021 was $583.00M.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers by Stock-Based Compensation
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation